Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors

Chemometrics and Intelligent Laboratory Systems

Volumn 109, Issue 2, 2011, Pages 101-112

  Moorthy, N S Hari Narayana ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

glucosidase inhibitors; Electrotopological descriptors; Hydrophobicity; Molecular connectivity (Chi); QSAR

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR;

ARTICLE; DRUG STRUCTURE; HYDROPHILICITY; HYDROPHOBICITY; MATHEMATICAL MODEL; MULTIPLE REGRESSION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY; STRUCTURE ANALYSIS; VALIDATION PROCESS;

EID: 80055094177     PISSN: 01697439     EISSN: 18733239     Source Type: Journal    
DOI: 10.1016/j.chemolab.2011.02.010     Document Type: Article

References (61)

1. Pili R., Chang J., Partis R.A., Mueller R.A., Chrest F.J., Passaniti A. The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Research 1995, 55:2920-2926.
2. Humphries M.J., Matsumoto K., White S.L., Olden K. Inhibition of experimental metastasis by castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Research 1986, 46:5215-5222.
3. Silva C.H.T.P., Taft C.A. Computer aided molecular design of novel glucosidase inhibitors for AIDS treatment. Journal of Biomolecular Structure and Dynamics 2004, 22:59-63.
4. Fischer P.B., Colin M., Karlson G.B., James W., Butters T.D., Davis S.J., Gordon S., Dwek R.A., Platt F.M. The α-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. Journal of Virology 1995, 69:5791-5797.
5. Taylor D.L., Kang M.S., Brennan T.M., Bridges C.G., Sunkara P.S., Tyms A.S. Inhibition of α-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl Castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus infected T cells. Antimicrobial Agents and Chemotherapy 1994, 38:1780-1787.
6. Gamblin D.P., Scanlan E.M., Davis B.G. Glycoprotein synthesis: an update. Chemical Reviews 2009, 109:131-163.
7. Hwangseo P., Kyo Y.H., Young H.K., Kyung H.O., Jae Y.L., Keun K. Discovery and biological evaluation of novel α-glucosidase inhibitors with in vivo antidiabetic effect. Bioorganic & Medicinal Chemistry Letters 2008, 18:3711-3715.
8. Rawling A.J., Lomas H., Adam W.P., Marvin J.R.L., Dominic S.A., Shane J.S.R., Sarah F.J., George W.J.F., Raymond A.D., John H.J., Terry D.B. Synthesis and biological characterization of novel N-alkyl deoxynojirimycin α-glucosidase inhibitors. ChemBioChem 2009, 10:1101-1105.
9. Karthikeyan C., Moorthy N.S.H.N., Trivedi P. QSAR study of substituted 2-pyridinyl quanidine as selective urokinase-type plasminogen activator (uPA) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2009, 24:6-13.
10. Kavitha B., Nagakumar B., Ki H.P., Keun W.L. Binding mode analyses and pharmacophore model development for sulphonamide chalcone derivatives, a new class of α-glucosidase inhibitors. Journal of Molecular Graphics & Modelling 2008, 26:1202-1212.
11. Tomich C.H., da Silva P., Ivone C., Taft C.A. Homology modelling and molecular interaction field studies of α-glucosidase as a guide to structure based drug design of novel proposed anti-HIV inhibitors. Journal of Computer-Aided Drug Design 2005, 19:83-92.
12. Yan L., Zhuofeng K., Jianfang C., Wen-Hua C., Lin M., Bo W. Synthesis, inhibitory activities and QSAR study of xanthone derivatives as α-glucosidase inhibitors. Bioorganic & Medicinal Chemistry 2008, 16:7185-7192.
13. Park J.-H., Ko S., Park H. Towards the virtual screening of α-glucosidase inhibitors with the homology-modeled protein structure. Bulletin of the Korean Chemical Society 2008, 29(5):921-927.
14. Karim K., Khatmi D., Saihi Y., Ferkous F., Brahimi M. Quantitative structure activity relationship for the computational prediction of α-glucosidase inhibitory activity. Chemometrics and Intelligent Laboratory Systems 2009, 97:118-126.
15. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. Prediction of the relationship between the structural features of andrographolide derivatives and α-glucosidase inhibitory activity: A quantitative structure activity relationship (QSAR) study. Journal of Enzyme Inhibition and Medicinal Chemistry 2011, 26:78-87. 10.3109/14756361003724760.
16. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. QSAR analysis of isosteviol derivatives as α-glucosidase inhibitors with element count and other descriptors. Letters in Drug Design & Discovery 2011, 8:14-25.
17. N.S.H.N. Moorthy, M.J. Ramos, P.A. Fernandes Topological, hydrophobicity and other descriptors on α-glucosidase inhibition: A QSAR study on xanthone derivatives, Journal of Enzyme Inhibition and Medicinal Chemistry (Article in press) DOI: 10.3109/14756366.2010.549089.
18. Hall L.H., Kier L.B., Brown B.B. Molecular similarity based on novel atom-type electrotopological state indices. Journal of Chemical Information and Computer Sciences 1995, 35(6):1074-1080.
19. Bagchi M.C., Mills D., Basak S.C. Quantitative structure activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. smegamtis using theoretical molecular descriptors. Journal of Molecular Modeling 2007, 13:111-120.
20. Hall L.H., Kier L.B. Electrotopological state indices for atom types: a novel combination of electronic, topological, and valence state information. Journal of Chemical Information and Computer Sciences 1995, 35(6):1039-1045.
21. Bansal R., Karthikeyan C., Moorthy N.S.H.N., Trivedi P. QSAR analysis of some phthalimide analogues based inhibitors of HIV-1 integrase. Arkivoc 2007, XV:66-81.
22. Moorthy N.S.H.N., Trivedi P. QSAR modelling of some 2-methoxy acridones: cytotoxic in multi drug resistant cells. International Journal of Cancer Research 2006, 2:267-276.
23. Sirichai A., Kasem S., Sophon R., Amron P., Nattaya N., Warinthorn C., Sujitra D., Siruntorn Y. Structure activity relationships of trans-cinnamic acid derivatives on α-glucosidase inhibition. Bioorganic & Medicinal Chemistry Letters 2004, 14:2893-2896.
24. Woo D.S., Jin H.K., Jae E.K., Hyung W.R., Marcus J.C.L., Hyun S.L., Min S.Y., Ki H.P. Sulfonamide chalcone as a new class of α-glucosidase inhibitors. Bioorganic & Medicinal Chemistry Letters 2005, 15:5514-5516.
25. Sonei S., Satoshi M., Hiroyasu T., Ryu Y., Shizuo K., Mikiko S., Yuichi H. Novel α-glucosidase inhibitors with a tetrachloropthalimide skeleton. Bioorganic & Medicinal Chemistry Letters 2000, 10:1081-1084.
26. Babu H.T., Rao V.R.S., Tiwari A.K., Babu K.S., Srinivas P.V., Amtul Z.A., Rao J.M. Synthesis and biological evaluation of novel 8-aminomethylated oroxylin A analogues as α-glucosidase inhibitors. Bioorganic & Medicinal Chemistry Letters 2008, 18:1659-1662.
27. V-Life Technologies, molecular design suite ™ 3.5, Pune, India 2008.
28. Statistica 8.0 statistical software 2008, StatSoft, Inc., Tulsa, OK, USA.
29. Balaji S., Karthikeyan C., Moorthy N.S.H.N., Trivedi P. QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorganic & Medicinal Chemistry Letters 2004, 14:6089-6094.
30. N.S.H.N. Moorthy, N.S. Cerqueira, M.J. Ramos, P.A. Fernandes, QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction, Medicinal Chemistry Research (Article in press). DOI 10.1007/s00044-010-9510-3.
31. Kiralj R., Ferreira M.M.C. Basic validation procedures for regression models in QSAR and QSPR studies: theory and applications. Journal of the Brazilian Chemical Society 2009, 20:770-787.
32. Tropsha A., Gramatica P., Gombar V.K. The importance of earnest, validation is the absolute essential application and interpretation of QSPR models. QSAR and Combinatorial Science 2003, 22:69-77.
33. Golbraikh A., Tropsha A. Beware of Q2. Journal of Molecular Graphics & Modelling 2002, 20:269-276.
34. Gramatica P. Principle of QSAR model validation: internal and external. QSAR and Combinatorial Science 2007, 26:694-701.
35. Tuppurainen K., Viisas M., Laatikainen R., Perkyl M. Evaluation of a novel eigenvalue (EEVA) molecular descriptor for QSAR/QSPR studies: validation using a benchmark steroid data set. Journal of Chemical Information and Computer Sciences 2002, 42(3):607-613.
36. Roy P.P., Roy K. On some aspects of variable selected for partial least squares regression models. QSAR and Combinatorial Science 2008, 27:302-313.
37. Guha R., Van Drie J.H. Structure-activity landscape index: identifying and quantifying activity cliffs. Journal of Chemical Information and Modeling 2008, 48:646-658.
38. Wawer M., Peltason L., Bajorath J. Elucidation of structure-activity relationship pathways in biological screening data. Journal of Medicinal Chemistry 2009, 52:1075-1080.
39. Peltason L., Bajorath J. SAR index: quantifying the nature of structure-activity relationships. Journal of Medicinal Chemistry 2007, 50:5571-5578.
40. Cook R.D. Influential observations in linear-regression. Journal of the American Statistical Association 1979, 74:169-174.
41. N.S.H.N. Moorthy, S.F. Sousa, M.J. Ramos, P.A. Fernandes, Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors, Journal of Enzyme Inhibition and Medicinal Chemistry (Article in press). DOI: 10.3109/14756366.2011.552885.
42. O'Brien R.M. A caution regarding rules of thumb for variance inflation factors. Quality and Quantity 2007, 41:673-690.
43. Neter J., Wasserman W., Kunter M.H. Applied linear statistical models: regression, analysis of variance, and experimental designs 1990, Irwin, Homewood (IL). third ed.
44. Wood F.S. Effect of centering on collinearity and interpretation of the constant. The American Statistician 1984, 38:88-90.
45. Gujarati D.N. Qualitative response regression models. Basic Econometrics 2003, McGraw-Hill, Boston. fourth ed.
46. N.S.H.N. Moorthy, N.M.F.S. Cerqueira, M.J. Ramos, P.A. Fernandes, QSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors, Medicinal Chemistry Research (Article in press). DOI: 10.1007/s00044-011-9580-x.
47. Durbin J., Watson G.S. Testing for serial correlation in least squares regression.1. Biometrika 1950, 37:409-428.
48. Durbin J., Watson G.S. Testing for serial correlation in least squares regression.2. Biometrika 1951, 38:159-178.
49. Hill R.J., Flack H.D. The use of the Durbin-Watson statistic in Rietveld analysis. Journal of Applied Crystallography 1987, 20:356-361.
50. Ernesto E., Enrique M. 3D Connectivity indices in QSPR/QSAR studies. Journal of Chemical Information and Computer Sciences 2001, 41(3):791-797.
51. Pogliani L. How far are molecular connectivity descriptors from IS molecular pseudoconnectivity descriptors?. Journal of Chemical Information and Computer Sciences 2001, 41:836-847.
52. Moorthy N.S.H.N., Karthikeyan C., Trivedi P. QSAR studies on cytotoxic acridine 5,7 diones: a comparative study using P_VSA descriptors and topological descriptors. Indian Journal of Chemistry Section B 2007, 46B:177-184.
53. Nys G.G., Rekker R.F. Statistical analysis of a series of partition coefficients with special reference to the predictability of folding of drug molecules Introduction of hydrophobic fragmental constants (f values). Chimie Therapeutique 1973, 8:521-535.
54. Nys G.G., Rekker R.F. The concept of hydrophobic fragmental constants (f-values). II. Extension of its applicability to the calculation of lipophilicities of aromatic and heteroaromatic structures. European Journal of Medicinal Chemistry-Chimie Therapeutique 1974, 9:361-375.
55. Kellogg G.E., Joshi G.S., Abraham D.J. New tools for modeling and understanding hydrophobicity and hydrophobic interactions. Medicinal Chemistry Research 1992, 1:444-453.
56. Kellogg G.E., Abraham D.J. KEY, LOCK, and LOCKSMITH: complementary hydropathic map predictions of drug structure from a known receptor-receptor structure from known drugs. Journal of Molecular Graphics 1992, 10:212-217.
57. Kellogg G.E., Abraham D.J. Hydrophobicity: is LogPo/w more than the sum of its parts?. European Journal of Medicinal Chemistry 2000, 35:651-661.
58. Kier L.B., Hall L.H. Molecular Structure Description: The Electrotopological State 1999, Academic Press, New York.
59. Kier L.B., Hall L.H. Inhibition of salicylamide binding: a electrotopological state analysis. Medicinal Chemistry Research 1992, 2:497-502.
60. Hall L.H. Electrotopological state indices for atom types: a novel combination of electronic, topological, and valence state information. Journal of Chemical Information and Computer Sciences 1995, 35:1039-1045.
61. Hall L.H., Mohney B., Kier L.B. The electrotopological state: an atom index for QSAR. Quantitative Structure-Activity Relationships 1991, 10:43-51.